Advances in Self-Double-Emulsifying Drug Delivery Systems
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: 10 March 2025 | Viewed by 81
Special Issue Editors
Interests: physiochemical properties of drugs; formulations; pharmacokinetics and pharmacodynamics; infectious diseases and cancer
Interests: self-emulsifying drug delivery systems; lipophilic drugs; lipophilic systems; natural oils; transdermal drug delivery; oral drug delivery; pseudo ternary phase diagrams; tuberculosis; malaria; tropical diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nearly 40–60% of all newly developed drugs are characteristically lipophilic in nature, rendering aqueous solubility problematic. To solve solubility issues, lipophilic drug delivery systems are a good method to increase the bioavailability of the said lipophilic drugs. Of these systems, self-emulsifying drug delivery systems are superior to other lipid-based formulations in terms of possessing a higher solubilization tendency, having robust formulation advantages, easier scalability in the industrial milieu, providing drug protection against certain environments, such as the gastrointestinal tract, inhibiting drug efflux as mediated by P-glycoprotein, enhancing lymphatic drug uptake, improving control over drug plasma concentration profiles, enhancing stability, and increasing drug loading efficiency. Moreover, self-double-emulsifying drug delivery systems (SDEDDSs) have been shown to significantly enhance the intestinal permeability of Biopharmaceutics Classification System (BCS), class III drugs, and are considered thermodynamically more stable than double emulsions. It has been reported that SDEDDSs display significant improvement in drug absorption without any severe toxic effects, and prolonged drug release profiles can be created through this system. Drugs, including peptide and protein components that are normally parenterally administered, have been successfully delivered orally by means of this drug delivery system. Solidification of SDEDDSs for the purpose of dose reduction of orally administered BCS class III drugs is furthermore possible, and even topical and/or transdermal SDEDDSs have been formulated that depict enhanced permeability efficacy.
This Special Issue aims to collect research and review papers on the advances made in SDEDDSs in the pharmaceutical field and will summarize the latest findings on SDEDDSs published as well as provide direction for future research. We invite researchers and production pharmacists to publish original research and/or review papers with expert opinions and perceptions in the area of therapeutics.
Prof. Dr. Lissinda Hester Du Plessis
Dr. Joe Viljoen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- characterization
- dosage form
- lipophilic drug delivery systems
- lipophilic drugs
- permeability
- self-double-emulsifying drug delivery systems
- self-emulsification
- solubility
- stability
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
